These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 34247883)

  • 1. IgA Nephropathy: Core Curriculum 2021.
    Pattrapornpisut P; Avila-Casado C; Reich HN
    Am J Kidney Dis; 2021 Sep; 78(3):429-441. PubMed ID: 34247883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on treatment of immunoglobulin A nephropathy.
    Zhang YM; Zhang H
    Nephrology (Carlton); 2018 Oct; 23 Suppl 4():62-67. PubMed ID: 30298661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and classification of IgA nephropathy.
    Yu HH; Chiang BL
    Autoimmun Rev; 2014; 13(4-5):556-9. PubMed ID: 24434362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical and pathological manifestations of Chinese childhood patients with primary IgA nephropathy: a national collaborative study of 33 hospitals].
    ; Jiang XY
    Zhonghua Er Ke Za Zhi; 2007 Apr; 45(4):272-8. PubMed ID: 17706064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glomerular diseases: emerging tests and therapies for IgA nephropathy.
    Canetta PA; Kiryluk K; Appel GB
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):617-25. PubMed ID: 24071652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy.
    Tanaka M; Seki G; Someya T; Nagata M; Fujita T
    Clin Dev Immunol; 2011; 2011():470803. PubMed ID: 21318178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgA-dominant glomerulonephritis with a membranoproliferative pattern of injury.
    Andeen NK; Jefferson JA; Akilesh S; Alpers CE; Bissonnette ML; Finn LS; Higgins J; Houghton DC; Kambham N; Magil A; Najafian B; Nicosia RF; Troxell ML; Smith KD
    Hum Pathol; 2018 Nov; 81():272-280. PubMed ID: 30420049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.
    Cassol CA; Bott C; Nadasdy GM; Alberton V; Malvar A; Nagaraja HN; Nadasdy T; Rovin BH; Satoskar AA
    Nephrol Dial Transplant; 2020 Dec; 35(12):2123-2129. PubMed ID: 31369128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [IgA nephropathy].
    Floege J
    Urologie; 2024 Jan; 63(1):103-111. PubMed ID: 38170257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges.
    Gutiérrez E; Carvaca-Fontán F; Luzardo L; Morales E; Alonso M; Praga M
    Nephron; 2020; 144(11):555-571. PubMed ID: 32818944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgA Nephropathy.
    Rodrigues JC; Haas M; Reich HN
    Clin J Am Soc Nephrol; 2017 Apr; 12(4):677-686. PubMed ID: 28159829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy.
    Zhao L; Peng L; Yang D; Chen S; Lan Z; Zhu X; Yuan S; Chen G; Liu Y; Liu H
    Clin Immunol; 2020 Aug; 217():108483. PubMed ID: 32479989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of complement in IgA nephropathy.
    Tortajada A; Gutierrez E; Pickering MC; Praga Terente M; Medjeral-Thomas N
    Mol Immunol; 2019 Oct; 114():123-132. PubMed ID: 31351413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of IgA nephropathy: Recent advances and prospects.
    Coppo R
    Nephrol Ther; 2018 Apr; 14 Suppl 1():S13-S21. PubMed ID: 29606258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cells in IgA nephropathy: role in pathogenesis, clinical significance and potential therapeutic target.
    Ruszkowski J; Lisowska KA; Pindel M; Heleniak Z; Dębska-Ślizień A; Witkowski JM
    Clin Exp Nephrol; 2019 Mar; 23(3):291-303. PubMed ID: 30406499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of progressive IgA nephropathy: an update.
    Wang W; Chen N
    Contrib Nephrol; 2013; 181():75-83. PubMed ID: 23689569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunoglobulin A nephropathy].
    Seikrit C; Rauen T; Floege J
    Internist (Berl); 2019 May; 60(5):432-439. PubMed ID: 30895344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
    Nagy J; Sági B; Máté J; Vas T; Kovács T
    Orv Hetil; 2017 Dec; 158(49):1946-1952. PubMed ID: 29199436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.
    Rizk DV; Maillard N; Julian BA; Knoppova B; Green TJ; Novak J; Wyatt RJ
    Front Immunol; 2019; 10():504. PubMed ID: 30941137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.